Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of NOX-H94 for anemia of chronic disease in cancer patients
2012-001525-27Phase 2Terminated
- Sponsor
- TME Pharma
- Start
- May 2012
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of lexaptepid pegol in anemia of inflammation (AI), sponsored by TME Pharma. Primary endpoint: Primary efficacy endpoint. Started May 2012; status: terminated.
02
Drugs
lexaptepid pegol
03
Conditions
anemia of inflammation (AI)
Beyond the preview
Go deeper on 2012-001525-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001525-27.